As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh carries a market capitalization of 8.82B, placing it among publicly traded companies globally. Its enterprise value stands at -27.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.82B |
| Enterprise Value | -27.17B |
As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh has 6.71M shares outstanding.
| Shares Outstanding | 6.71M |
These figures are as of June 30, 2026. The price-to-sales ratio is 34.89, and the price-to-book ratio stands at 0.16.
| PS Ratio | 34.89 |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | -2.19 |
| P/OCF Ratio | -2.59 |
As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh maintains a current ratio of 2.83, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.01, indicating elevated leverage, while an interest coverage ratio of -30.88 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.83 |
| Quick Ratio | 2.60 |
| Debt / Equity | 20.01 |
| Debt / EBITDA | -0.61 |
| Interest Coverage | -30.88 |
Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh posted a negative return on equity (ROE) of -61.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.27, reflecting losses generated across the asset base. The company generates approximately 40.78M in revenue per employee across its workforce of 43.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -61.20 |
| Return on Assets (ROA) | -39.27 |
| Revenue Per Employee | 40.78M |
| Employee Count | 43.00 |
Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh recorded 12.56M in income tax expense. The company reported a pretax loss of -24.50B and -24.52B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 12.56M |
As of the close on November 17, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh's stock has declined approximately 50.08% over the past 52 weeks. The 50-day moving average sits at 1,839.54, while the 200-day moving average is 2,280.22.
| 52-Week Price Change | -50.08% |
| 50-Day Moving Average | 1,839.54 |
| 200-Day Moving Average | 2,280.22 |
Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh generated 1.75B in revenue and converted that into -24.52B in net income, yielding earnings per share of -527.25. EBITDA reached -18.58B, while operating income came in at -21.05B.
| Revenue | 1.75B |
| Gross Profit | 1.63B |
| Operating Income | -21.05B |
| Pretax Income | -24.50B |
| Net Income | -24.52B |
| EBITDA | -18.58B |
| EBIT | -21.05B |
| Earnings Per Share (EPS) | -527.25 |
As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh holds 47.28B in cash and equivalents against 11.28B in total debt, resulting in a net debt position of -26.36B. Total book value stands at 56.38B, with working capital of 33.25B providing operational flexibility.
| Cash & Cash Equivalents | 47.28B |
| Total Debt | 11.28B |
| Net Debt | -26.36B |
| Equity (Book Value) | 56.38B |
| Book Value Per Share | 8,407.92 |
| Working Capital | 33.25B |
NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh produced -23.64B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.31B in capital expenditures, free cash flow totaled -27.95B - equivalent to -601.08 per share.
| Operating Cash Flow | -23.64B |
| Capital Expenditures | -4.31B |
| Free Cash Flow | -27.95B |
| FCF Per Share | -601.08 |
These figures cover the twelve months ended June 30, 2026. The operating margin of -1,200.62 and net profit margin of -1,397.95 provide insight into operational efficiency.
| Operating Margin | -1,200.62 |
| Pretax Margin | -1,397.23 |
| Profit Margin | -1,397.95 |
| EBITDA Margin | -1,059.47 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -45.67: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -548.15, meaning NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -548.15 |
| FCF Yield | -45.67 |
NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh's most recent stock split took place on June 10, 2026 with a 5:1 split ratio.
| Last Split Date | 6/10/2026 |
| Split Ratio | 5:1 |
As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh has an Altman Z-Score of -9.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.83 |